NVCR logo

NovoCure Limited (NVCR) EBITDA

annual EBITDA:

-$109.58M+$67.87M(+38.25%)
December 31, 2024

Summary

  • As of today (May 29, 2025), NVCR annual EBITDA is -$109.58 million, with the most recent change of +$67.87 million (+38.25%) on December 31, 2024.
  • During the last 3 years, NVCR annual EBITDA has fallen by -$71.20 million (-185.49%).
  • NVCR annual EBITDA is now -344.42% below its all-time high of $44.83 million, reached on December 31, 2020.

Performance

1-year change

+38.25%

3-year change

-185.49%

5-year change

-911.13%

15-year change

-258.6%

NVCR EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

16.3%
NVCR annual EBITDA is higher than 16.3% of companies in Healthcare sector

Range

All-time high

$44.83M
NVCR annual EBITDA is currently -344.42% below its historical high of $44.83 million

3-year low

-$177.45M

Earnings dates

Last annual earnings report date

Dec 31, 2024
NVCR previous annual earnings announcement was published on Dec 31, 2024

Next annual earnings report date

N/A
NVCR next annual earnings announcement has not yet been scheduled

OtherNVCRincome statement metrics

Annual revenue

$605.22M
NVCR annual revenue is $605.22 million

annual net income

-$168.63M
NVCR annual net profit is -$168.63 million

annual EBIT

-$120.82M
NVCR annual earnings before interest & taxes is -$120.82 million

Annual EPS

-$1.56
NVCR annual earnings per share is -$1.56

quarterly EBITDA:

-$34.54M-$24.02M(-228.23%)
March 31, 2025

Summary

  • As of today (May 29, 2025), NVCR quarterly EBITDA is -$34.54 million, with the most recent change of -$24.02 million (-228.23%) on March 31, 2025.
  • Over the past year, NVCR quarterly EBITDA has increased by +$4.17 million (+10.76%).
  • NVCR quarterly EBITDA is now -274.02% below its all-time high of $19.85 million, reached on December 31, 2020.

Performance

3-month change

-228.23%

1-year change

+10.76%

3-year change

-2014.63%

5-year change

-2213.46%

NVCR quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

13.45%
NVCR quarterly EBITDA is higher than 13.45% of companies in Healthcare sector

Range

All-time high

$19.85M
NVCR quarterly EBITDA is currently -274.02% below its historical high of $19.85 million

3-year low

-$59.94M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
NVCR previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Jul 25, 2025
NVCR next earnings announcement is scheduled for Jul 25, 2025

OtherNVCRincome statement metrics

Quarterly revenue

$154.99M
NVCR quarterly revenue is $154.99 million

quarterly net income

-$34.32M
NVCR quarterly net profit is -$34.32 million

quarterly EBIT

-$37.87M
NVCR quarterly earnings before interest & taxes is -$37.87 million

Quarterly EPS

-$0.31
NVCR quarterly earnings per share is -$0.31

TTM EBITDA:

-$105.42M+$4.17M(+3.80%)
March 31, 2025

Summary

  • As of today (May 29, 2025), NVCR TTM EBITDA is -$105.42 million, with the most recent change of +$4.17 million (+3.80%) on March 31, 2025.
  • Over the past year, NVCR TTM EBITDA has increased by +$53.21 million (+33.54%).
  • NVCR TTM EBITDA is now -316.87% below its all-time high of $48.61 million, reached on March 31, 2021.

Performance

3-month change

+3.8%

1-year change

+33.54%

3-year change

-171.26%

5-year change

-750.49%

NVCR TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector rank

17.74%
NVCR TTM EBITDA is higher than 17.74% of companies in Healthcare sector

Range

All-time high

$48.61M
NVCR TTM EBITDA is currently -316.87% below its historical high of $48.61 million

3-year low

-$202.18M

Earnings dates

Last quarterly earnings report date

Mar 31, 2025
NVCR previous earnings announcement was published on Mar 31, 2025

Next quarterly earnings report date

Jul 25, 2025
NVCR next earnings announcement is scheduled for Jul 25, 2025

OtherNVCRincome statement metrics

TTM revenue

$621.71M
NVCR TTM revenue is $621.71 million

TTM net income

-$164.19M
NVCR TTM net profit is -$164.19 million

TTM EBIT

-$117.16M
NVCR TTM earnings before interest & taxes is -$117.16 million

TTM EPS

-$1.51
NVCR TTM earnings per share is -$1.51

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

annual EBITDA

-$109.58M
NVCR annual EBITDA is -$109.58 million

annual net income

-$168.63M
NVCR annual net profit is -$168.63 million

annual interest expense

$10.34M
NVCR annual interest expense is $10.34 million

annual income tax

$37.47M
NVCR annual income tax is $37.47 million

annual D&A

$11.23M
NVCR annual depreciation & amortization is $11.23 million

NVCR EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+38.3%+10.8%+33.5%
3 y3 years-185.5%-2014.6%-171.3%
5 y5 years-911.1%-2213.5%-750.5%

NVCR EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-185.5%+38.3%-2014.6%+42.4%-171.3%+47.9%
5 y5-year-344.4%+38.3%-274.0%+42.4%-316.9%+47.9%
alltimeall time-344.4%+38.3%-274.0%+42.4%-316.9%+47.9%

NVCR EBITDA History

DateAnnualQuarterlyTTM
Mar 2025
-
-$34.54M(+228.2%)
-$105.42M(-3.8%)
Dec 2024
-$109.58M(-38.2%)
-$10.52M(-64.5%)
-$109.58M(+5.8%)
Sep 2024
-
-$29.63M(-3.5%)
-$103.61M(-19.9%)
Jun 2024
-
-$30.72M(-20.6%)
-$129.41M(-18.4%)
Mar 2024
-
-$38.70M(+751.8%)
-$158.63M(-10.6%)
Dec 2023
-$177.45M(+161.4%)
-$4.54M(-91.8%)
-$177.45M(-12.2%)
Sep 2023
-
-$55.44M(-7.5%)
-$202.18M(+19.9%)
Jun 2023
-
-$59.94M(+4.2%)
-$168.69M(+32.6%)
Mar 2023
-
-$57.53M(+96.6%)
-$127.22M(+87.4%)
Dec 2022
-$67.89M(+76.9%)
-$29.27M(+33.3%)
-$67.89M(+6.7%)
Sep 2022
-
-$21.95M(+18.8%)
-$63.66M(+34.0%)
Jun 2022
-
-$18.47M(-1124.1%)
-$47.52M(+22.3%)
Mar 2022
-
$1.80M(-107.2%)
-$38.86M(+1.2%)
Dec 2021
-$38.38M(-185.6%)
-$25.03M(+330.3%)
-$38.38M(-690.8%)
Sep 2021
-
-$5.82M(-40.7%)
$6.50M(-78.0%)
Jun 2021
-
-$9.81M(-530.1%)
$29.52M(-39.3%)
Mar 2021
-
$2.28M(-88.5%)
$48.61M(+8.4%)
Dec 2020
$44.83M(+231.9%)
$19.85M(+15.3%)
$44.83M(+33.6%)
Sep 2020
-
$17.21M(+85.7%)
$33.57M(+51.6%)
Jun 2020
-
$9.27M(-720.8%)
$22.15M(+36.7%)
Mar 2020
-
-$1.49M(-117.4%)
$16.21M(+20.0%)
Dec 2019
$13.51M
$8.58M(+48.3%)
$13.51M(+448.1%)
DateAnnualQuarterlyTTM
Sep 2019
-
$5.79M(+73.9%)
$2.46M(-139.4%)
Jun 2019
-
$3.33M(-179.4%)
-$6.26M(-56.5%)
Mar 2019
-
-$4.19M(+70.2%)
-$14.38M(-30.4%)
Dec 2018
-$20.67M(-32.4%)
-$2.46M(-16.1%)
-$20.67M(+6.2%)
Sep 2018
-
-$2.94M(-38.8%)
-$19.47M(-4.6%)
Jun 2018
-
-$4.80M(-54.2%)
-$20.40M(-30.4%)
Mar 2018
-
-$10.47M(+730.6%)
-$29.32M(-4.1%)
Dec 2017
-$30.56M(-72.2%)
-$1.26M(-67.4%)
-$30.56M(-33.3%)
Sep 2017
-
-$3.87M(-71.8%)
-$45.80M(-33.3%)
Jun 2017
-
-$13.72M(+17.1%)
-$68.64M(-24.4%)
Mar 2017
-
-$11.71M(-29.0%)
-$90.75M(-17.4%)
Dec 2016
-$109.88M(+8.1%)
-$16.50M(-38.2%)
-$109.88M(-11.1%)
Sep 2016
-
-$26.71M(-25.4%)
-$123.61M(+2.8%)
Jun 2016
-
-$35.83M(+16.2%)
-$120.25M(+8.3%)
Mar 2016
-
-$30.84M(+2.0%)
-$111.03M(+9.3%)
Dec 2015
-$101.62M(+29.8%)
-$30.24M(+29.5%)
-$101.62M(+8.1%)
Sep 2015
-
-$23.34M(-12.3%)
-$94.00M(+6.8%)
Jun 2015
-
-$26.62M(+24.3%)
-$88.05M(+43.3%)
Mar 2015
-
-$21.42M(-5.3%)
-$61.43M(+53.5%)
Dec 2014
-$78.30M(+14.1%)
-$22.61M(+30.0%)
-$40.01M(+130.0%)
Sep 2014
-
-$17.39M
-$17.39M
Dec 2013
-$68.64M
-
-

FAQ

  • What is NovoCure Limited annual EBITDA?
  • What is the all time high annual EBITDA for NovoCure Limited?
  • What is NovoCure Limited annual EBITDA year-on-year change?
  • What is NovoCure Limited quarterly EBITDA?
  • What is the all time high quarterly EBITDA for NovoCure Limited?
  • What is NovoCure Limited quarterly EBITDA year-on-year change?
  • What is NovoCure Limited TTM EBITDA?
  • What is the all time high TTM EBITDA for NovoCure Limited?
  • What is NovoCure Limited TTM EBITDA year-on-year change?

What is NovoCure Limited annual EBITDA?

The current annual EBITDA of NVCR is -$109.58M

What is the all time high annual EBITDA for NovoCure Limited?

NovoCure Limited all-time high annual EBITDA is $44.83M

What is NovoCure Limited annual EBITDA year-on-year change?

Over the past year, NVCR annual EBITDA has changed by +$67.87M (+38.25%)

What is NovoCure Limited quarterly EBITDA?

The current quarterly EBITDA of NVCR is -$34.54M

What is the all time high quarterly EBITDA for NovoCure Limited?

NovoCure Limited all-time high quarterly EBITDA is $19.85M

What is NovoCure Limited quarterly EBITDA year-on-year change?

Over the past year, NVCR quarterly EBITDA has changed by +$4.17M (+10.76%)

What is NovoCure Limited TTM EBITDA?

The current TTM EBITDA of NVCR is -$105.42M

What is the all time high TTM EBITDA for NovoCure Limited?

NovoCure Limited all-time high TTM EBITDA is $48.61M

What is NovoCure Limited TTM EBITDA year-on-year change?

Over the past year, NVCR TTM EBITDA has changed by +$53.21M (+33.54%)
On this page